文献速递泌尿男性生殖肿瘤

膀胱内cretostimogene溶瘤免疫治疗高危BCG无应答伴原位癌NMIBC的III期单臂研究

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2026-01-01

BOND-003 Cohort C是一项单臂国际III期研究,评估膀胱内cretostimogene在112例高危BCG无应答伴原位癌的非肌层浸润性膀胱癌患者中的疗效与安全性。

要点

  • cretostimogene在高危BCG无应答伴原位癌NMIBC中完全缓解率达75%。
  • 安全性以低级别短暂不良事件为主,无3/4级治疗相关不良事件。
  • 该疗法有望成为保留膀胱的创新治疗选择。

核心结论

  • cretostimogene在高危BCG无应答伴原位癌NMIBC中显示出有临床意义的抗肿瘤反应,安全性以低级别短暂事件为主。

研究设计与样本

  • BOND-003 Cohort C为单臂、国际、III期研究,在北美、亚洲和澳大利亚的41个中心开展。
  • 研究纳入年龄≥18岁、ECOG体能状态0-2、病理确诊高危BCG无应答伴原位癌(可伴已切除的高级别Ta或T1)的NMIBC患者。
  • 主要终点为至少接受一剂cretostimogene且完成3个月评估的患者中经中心确认的任意时间完全缓解;安全性在至少接受一剂的患者中评估。

主要发现

  • 112例中71例(63%)发生至少一次治疗相关不良事件,最常见为膀胱痉挛28例(25%)、尿频25例(22%)、尿急23例(21%)。
  • 无3级或4级治疗相关不良事件,无治疗相关停药或死亡。
  • 2例(2%)发生严重治疗相关不良事件(非感染性膀胱炎和膀胱出血各1例,均为2级)。

临床怎么用

  • cretostimogene可作为高危BCG无应答伴原位癌NMIBC患者保留膀胱的创新治疗选择,其完全缓解率高且安全性良好。

局限性

  • 本研究为单臂设计,无对照臂,结论需进一步随机对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are few bladder-sparing treatment options for high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer that are effective and have a manageable adverse event profile. Cretostimogene grenadenorepvec (hereafter, cretostimogene) is an oncolytic immunotherapy with dual mechanisms of action-it replicates in and lyses cancer cells with retinoblastoma-E2F pathway alterations and amplifies the immune response. We evaluated the response and safety/tolerability of cretostimogene in patients with high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer. METHODS: BOND-003 Cohort C is a single-arm, international, phase 3 study done in 41 centres (community practices and academic centres) located in North America, Asia, and Australia. Sites were selected through a study team-led qualification process that evaluated feasibility, protocol alignment, operational capabilities, and regulatory readiness, as applicable. We enrolled patients aged at least 18 years with Eastern Cooperative Oncology Group performance status of 0-2 and pathologically confirmed, high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without resected high-grade Ta or T1 disease. Patients received intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months. The primary endpoint was centrally confirmed complete response at any time in patients who received at least one dose of cretostimogene and completed the 3-month assessment; safety was assessed in those who received at least one dose of cretostimogene. This trial is registered with ClinicalTrials.gov (NCT04452591) and is ongoing. FINDINGS: Between Oct 9, 2020, and Aug 3, 2023, 165 patients were assessed for eligibility; 115 patients were enrolled in the study and 112 received cretostimogene. 83 (74%) were male and 29 (26%) were female; median age was 74·0 years (IQR 68·5-79·5). As of June 23, 2025, after a median follow-up of 25·8 months (IQR 22·1-33·1), complete response at any time was observed in 83 (75% [95% CI 66·3-83·2]) of 110 patients. 71 (63%) of 112 patients had at least one treatment-related adverse event, the most common being bladder spasm in 28 (25%) patients, pollakiuria in 25 (22%) patients, and micturition urgency in 23 (21%) patients; there were no grade 3 or 4 treatment-related adverse events and no treatment-related discontinuations or deaths. Two (2%) patients had serious treatment-related adverse events (one non-infective cystitis and one urinary bladder haemorrhage, both grade 2). INTERPRETATION: Cretostimogene showed clinically meaningful anti-tumour response, with an adverse event profile characterised predominantly by low-grade, transient events. Cretostimogene shows promise as an innovative bladder-sparing treatment for high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ. FUNDING: CG Oncology.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tyson MD, Nam JK, Joshi SS, et al. Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial. Lancet Oncol. 2026. PMID: 42508433. doi:10.1016/S1470-2045(26)00194-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。